FDA Announces Revisions To Tenofovir Disoproxil Fumarate Label To Include Pediatric Patients With Chronic HBV.
Healio (12/13) reports “the FDA announced revisions to the Viread [tenofovir disoproxil fumarate] label to include use in pediatric patients aged 2 years to less than 12 years with chronic hepatitis B based on 48-week safety and efficacy data.”